MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cisplatin resistance significantly limits ovarian cancer treatment efficacy.
• The underlying molecular mechanisms of cisplatin resistance in ovarian cancer remain incompletely understood.
• MicroRNAs (miRNAs) are increasingly recognized as key regulators in cancer progression and drug resistance.

Purpose of the Study:

• To investigate the role of miR-497 in cisplatin resistance in ovarian cancer.
• To explore the relationship between miR-497 expression, promoter methylation, and chemoresistance.
• To evaluate the therapeutic potential of miR-497 in overcoming cisplatin resistance.

Main Methods:

• Analysis of miR-497 expression in chemoresistant ovarian cancer cells and tissues.
• Investigation of miR-497 promoter methylation status.
• Correlation analysis of miR-497, mTOR, and p70S6K1 expression in clinical datasets.
• Utilizing an orthotopic ovarian tumor model with a Tet-On inducible miR-497 system.

Main Results:

• Reduced miR-497 expression was observed in chemoresistant ovarian cancer cells and tissues.
• Hypermethylation of the miR-497 promoter was identified as a cause for reduced expression.
• Low miR-497 levels were associated with a chemoresistant phenotype.
• mTOR and p70S6K1 expression were inversely correlated with miR-497 levels.
• Overexpression of miR-497 sensitized resistant ovarian tumors to cisplatin in vivo.

Conclusions:

• miR-497 plays a crucial role in regulating cisplatin sensitivity in ovarian cancer.
• miR-497 promoter hypermethylation contributes to its downregulation and subsequent chemoresistance.
• Restoring miR-497 levels can overcome cisplatin resistance in ovarian cancer models.
• miR-497 holds potential as a therapeutic supplement to enhance cisplatin treatment response.